Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study

Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugat...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Michael A., Cox, Kristin E., Neel, Nicholas, Amirfakhri, Siamak, Nishino, Hiroto, Clary, Bryan M., Hosseini, Mojgan, Natarajan, Gopalakrishnan, Mallya, Kavita, Mohs, Aaron M., Hoffman, Robert M., Batra, Surinder K., Bouvet, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221372/
https://www.ncbi.nlm.nih.gov/pubmed/37241027
http://dx.doi.org/10.3390/jpm13050857
_version_ 1785049440406470656
author Turner, Michael A.
Cox, Kristin E.
Neel, Nicholas
Amirfakhri, Siamak
Nishino, Hiroto
Clary, Bryan M.
Hosseini, Mojgan
Natarajan, Gopalakrishnan
Mallya, Kavita
Mohs, Aaron M.
Hoffman, Robert M.
Batra, Surinder K.
Bouvet, Michael
author_facet Turner, Michael A.
Cox, Kristin E.
Neel, Nicholas
Amirfakhri, Siamak
Nishino, Hiroto
Clary, Bryan M.
Hosseini, Mojgan
Natarajan, Gopalakrishnan
Mallya, Kavita
Mohs, Aaron M.
Hoffman, Robert M.
Batra, Surinder K.
Bouvet, Michael
author_sort Turner, Michael A.
collection PubMed
description Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (Panc Met) in a unique patient-derived orthotopic xenograft (PDOX) model. In orthotopic models, the mean tumor to background ratio was 1.787 (SD ± 0.336), and immunohistochemistry confirmed the expression of MUC5AC within tumor cells. MUC5AC-IR800 provides distinct visualization of pancreatic cancer liver metastasis in a PDOX mouse model, demonstrating its potential utility in staging laparoscopy and fluorescence-guided surgery.
format Online
Article
Text
id pubmed-10221372
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102213722023-05-28 Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study Turner, Michael A. Cox, Kristin E. Neel, Nicholas Amirfakhri, Siamak Nishino, Hiroto Clary, Bryan M. Hosseini, Mojgan Natarajan, Gopalakrishnan Mallya, Kavita Mohs, Aaron M. Hoffman, Robert M. Batra, Surinder K. Bouvet, Michael J Pers Med Brief Report Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (Panc Met) in a unique patient-derived orthotopic xenograft (PDOX) model. In orthotopic models, the mean tumor to background ratio was 1.787 (SD ± 0.336), and immunohistochemistry confirmed the expression of MUC5AC within tumor cells. MUC5AC-IR800 provides distinct visualization of pancreatic cancer liver metastasis in a PDOX mouse model, demonstrating its potential utility in staging laparoscopy and fluorescence-guided surgery. MDPI 2023-05-20 /pmc/articles/PMC10221372/ /pubmed/37241027 http://dx.doi.org/10.3390/jpm13050857 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Turner, Michael A.
Cox, Kristin E.
Neel, Nicholas
Amirfakhri, Siamak
Nishino, Hiroto
Clary, Bryan M.
Hosseini, Mojgan
Natarajan, Gopalakrishnan
Mallya, Kavita
Mohs, Aaron M.
Hoffman, Robert M.
Batra, Surinder K.
Bouvet, Michael
Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
title Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
title_full Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
title_fullStr Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
title_full_unstemmed Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
title_short Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
title_sort highly selective targeting of pancreatic cancer in the liver with a near-infrared anti-muc5ac probe in a pdox mouse model: a proof-of-concept study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221372/
https://www.ncbi.nlm.nih.gov/pubmed/37241027
http://dx.doi.org/10.3390/jpm13050857
work_keys_str_mv AT turnermichaela highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT coxkristine highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT neelnicholas highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT amirfakhrisiamak highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT nishinohiroto highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT clarybryanm highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT hosseinimojgan highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT natarajangopalakrishnan highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT mallyakavita highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT mohsaaronm highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT hoffmanrobertm highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT batrasurinderk highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy
AT bouvetmichael highlyselectivetargetingofpancreaticcancerintheliverwithanearinfraredantimuc5acprobeinapdoxmousemodelaproofofconceptstudy

Ejemplares similares